Aptevo Therapeutics (APVO) Share-based Compensation (2016 - 2023)
Historic Share-based Compensation for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $455000.0.
- Aptevo Therapeutics' Share-based Compensation rose 2674.09% to $455000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $2.2 million, marking a year-over-year increase of 3514.18%. This contributed to the annual value of $2.2 million for FY2023, which is 2169.81% up from last year.
- Per Aptevo Therapeutics' latest filing, its Share-based Compensation stood at $455000.0 for Q3 2023, which was up 2674.09% from $465000.0 recorded in Q2 2023.
- In the past 5 years, Aptevo Therapeutics' Share-based Compensation registered a high of $915000.0 during Q1 2023, and its lowest value of $178000.0 during Q4 2021.
- Its 5-year average for Share-based Compensation is $428000.0, with a median of $401000.0 in 2019.
- In the last 5 years, Aptevo Therapeutics' Share-based Compensation plummeted by 3056.13% in 2019 and then soared by 10056.18% in 2022.
- Over the past 5 years, Aptevo Therapeutics' Share-based Compensation (Quarter) stood at $269000.0 in 2019, then decreased by 26.39% to $198000.0 in 2020, then decreased by 10.1% to $178000.0 in 2021, then surged by 100.56% to $357000.0 in 2022, then rose by 27.45% to $455000.0 in 2023.
- Its Share-based Compensation was $455000.0 in Q3 2023, compared to $465000.0 in Q2 2023 and $915000.0 in Q1 2023.